Navigation Links
BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
Date:9/11/2008

NOVATO, Calif., Sept. 11 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Business and Corporate Development of BioMarin, will present a company update at the Merrill Lynch Global Pharmaceutical Conference in London on Thursday, September 18, 2008 at 10:35 a.m. BST.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please vi
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
2. BioMarin to Present at the Citi Biotech Day
3. BioMarin Announces Roll-Out of National PKU Registry
4. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
5. BioMarin to Present at the Collins Stewart Growth Conference
6. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
7. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
8. BioMarin to Host Research and Development Day June 5th
9. BioMarin to Present at the Bank of America Healthcare Conference
10. BioMarin Announces First Quarter 2008 Financial Results
11. BioMarin to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 The empty capsules ... rising ageing population and technological innovations in the ... industries are catalysing the growth of the empty ... http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report , The ... as new entrants/smaller firms to gauge the pulse ...
(Date:12/19/2014)... 2014   ISN has released its third ... publication series. With data aggregated from over ... 2013 within its online contractor management platform, ISNetworld, this ... indicator (KPI) statistics. The ... publication is available in two industry specific volumes: ...
(Date:12/17/2014)... “Never say, ‘I cannot do ... Department of Physics, advises young women pursuing careers ... SPIE Women in Optics 18-month planner ... ask questions.” , In the annual planner, women ... ranging from university professor and laboratory researcher to ...
(Date:12/17/2014)... This report is a professional ... For an overview analysis, the report introduces quartz ... structure, industry overview, policy analysis, and news analysis, ... has witnessed rapid development with key manufacturers increasing ... report mentions quartz tubing upstream raw materials and ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 32020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2
... 12 The Board of,Directors of Baxter International Inc. ... $0.2175 per share of Baxter common stock., This ... was,increased earlier this year by 30 percent. This quarterly ... record as of March 10, 2008., Baxter International ...
... Feb. 12 /PRNewswire-FirstCall/ . Maxygen, Inc.,(Nasdaq: MAXY ... of,improved protein drugs, today reported financial results for ... At December 31, 2007, cash, cash,equivalents and marketable ... December 31, 2006., "After a productive year ...
... Calif., Feb. 12 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... therapies for the treatment of cancer and,hepatitis C ... has,begun in its clinical trial designed to evaluate ... chemotherapy in patients with advanced,breast cancer. The primary ...
Cached Biology Technology:Maxygen Reports Fourth Quarter and Year End 2007 Financial Results 2Maxygen Reports Fourth Quarter and Year End 2007 Financial Results 3Maxygen Reports Fourth Quarter and Year End 2007 Financial Results 4Maxygen Reports Fourth Quarter and Year End 2007 Financial Results 5Maxygen Reports Fourth Quarter and Year End 2007 Financial Results 6Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer 4
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... Sorority and the Orthopaedic Research and Education Foundation (OREF) ... to close the gap between basic research and patient ... of the American Academy of Orthopaedic Surgeons (AAOS), these ... areas of musculoskeletal health: Bio-enhanced ...
... paint containing dangerous,concentrations of lead is being sold in ... refusing to remove the paint from store shelves. , ... the lead content of paint in,Cameroon to protect public ... (OK International) and co-author of a new,research study about ...
... Rochelle, NY, Mar 19, 2013Chronic fatigue, a persistent lack ... at least three times more prevalent among adult survivors ... or adolescence than in the general adult population, according ... Young Adult Oncology (JAYAO), ( http://www.liebertpub.com/JAYAO ) a ...
Cached Biology News:AAOS awards recognize innovative orthopaedic research 2AAOS awards recognize innovative orthopaedic research 3AAOS awards recognize innovative orthopaedic research 4US company identified as manufacture of lead paint in Africa 2Are survivors of childhood leukemia and lymphoma at greater risk of chronic fatigue as adults? 2
... DNA Engine Dyad thermal cycler is ... (PCR). The chassis accommodates a variety ... assemblies), which hold different types and ... graphical programming with point-and-click navigation. Peltier ...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
For demonstration of Helicobacter pylori...
... FLISP Assay with SR-101 Labeled Substrates ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
Biology Products: